Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 114Neoplasms 37Neoplasm Metastasis 24Stomach Neoplasms 22Pancreatic Neoplasms 19Colonic Neoplasms 15Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 13Sarcoma 10Esophageal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Small Cell Lung Carcinoma 8Sarcoma, Ewing 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Ovarian Neoplasms 6Gastrointestinal Neoplasms 6Uterine Cervical Neoplasms 5Solid Tumors 5Recurrence 5Neuroblastoma 5Intestinal Neoplasms 5Digestive System Neoplasms 5Cholangiocarcinoma 5Advanced Solid Tumor 5Rhabdomyosarcoma 4Gastrointestinal Diseases 4Endometrial Neoplasms 4Digestive System Diseases 4

Interventions

sapanisertib 2MLN 8237 2tovorafenib 1serabelisib 1pevonedistat 1TAK 733 1Paclitaxel 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Nonhematologic Malignancies × Irinotecan × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡